{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:43:34Z","timestamp":1793295814265,"version":"4.5.0"},"reference-count":203,"publisher":"Bentham Science Publishers Ltd.","issue":"7","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Recent evidence suggests a possible relationship between the immune system and schizophrenia\nspectrum disorders (SSDs), as neuroinflammation appears to play a role in major psychiatric\nconditions. Neuroinflammation is as a broad concept representing a physiological protective response\nto infection or injury, but in some cases, especially if chronic, it may represent an expression of maladaptive\nprocesses, potentially driving to clinical dysfunction and neurodegeneration. Several studies\nare concurrently highlighting the importance of microglia, the resident immune cells of the central\nnervous system, in a huge number of neurodegenerative diseases, including multiple sclerosis, Alzheimer\u2019s\nand Parkinson\u2019s diseases, as well as SSDs. A more fundamental phenomenon of maladaptive\ncoupling of microglia may contribute to the genesis of dysfunctional brain inflammation involved in\nSSDs, from the onset of their neurophenomenological evolution. Clozapine and other antipsychotic\ndrugs seem to express a provable immunomodulant effect and a more specific action on microglia,\nwhile neuroactive steroids and nonsteroidal anti-inflammatory drugs may reduce some SSDs symptoms\nin add-on therapy. Given these theoretical premises, this article aims to summarize and interpret\nthe available scientific evidence about psychotropic and anti-inflammatory drugs that could express an\nimmunomodulant activity on microglia.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570159x22666231128101725","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T09:30:52Z","timestamp":1701336652000},"page":"1233-1247","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Immunomodulatory Effects of Clozapine: More Than Just a Side Effect in\nSchizophrenia"],"prefix":"10.2174","volume":"22","author":[{"given":"Andrea","family":"Amerio","sequence":"first","affiliation":[{"name":"Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Genoa, Italy"},{"name":"IRCCS Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Magnani","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Arduino","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Fesce","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"de Filippis","sequence":"additional","affiliation":[{"name":"Psychiatry Unit, Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Parise","sequence":"additional","affiliation":[{"name":"Department of Geriatric-Rehabilitation,, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Costanza","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, University of Geneva (UNIGE), Geneva, Switzerland"},{"name":"Department of Psychiatry, Faculty of Biomedical Sciences, University of Italian Switzerland (USI) Lugano, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khoa D.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Stanford University, Palo Alto, CA, USA"},{"name":"Tranquis Therapeutics, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Saverino","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale Policlinico San Martino, Genoa, Italy"},{"name":"Department of Experimental Medicine (DiMeS), Section of Human Anatomy, University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"De Berardis","sequence":"additional","affiliation":[{"name":"NHS, Department\nof Mental Health, Psychiatric Service for Diagnosis and Treatment, Hospital &#34;G. Mazzini&#34;, Teramo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Aguglia","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI),\nSection of Psychiatry, University of Genoa, Genoa, Italy"},{"name":"IRCCS Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Escelsior","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Genoa, Italy"},{"name":"IRCCS Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Serafini","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Genoa, Italy"},{"name":"IRCCS Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"De Fazio","sequence":"additional","affiliation":[{"name":"Psychiatry Unit, Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Amore","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI),\nSection of Psychiatry, University of Genoa, Genoa, Italy"},{"name":"IRCCS Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1192\/bjp.bp.110.084384","volume":"198","author":"Owen M.J.","year":"2011","unstructured":"Owen M.J.; O\u2019Donovan M.C.; Thapar A.; Craddock N.; Neurodevelopmental hypothesis of Schizophrenia. Br J Psychiatry  2011,198(3),173-175","journal-title":"Br J Psychiatry"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"e329","DOI":"10.1038\/tp.2013.108","volume":"3","author":"Mullin A.P.","year":"2013","unstructured":"Mullin A.P.; Gokhale A.; Moreno-De-Luca A.; Sanyal S.; Waddington J.L.; Faundez V.; Neurodevelopmental disorders: Mechanisms and boundary definitions from genomes, interactomes and proteomes. Transl Psychiatry  2013,3(12),e329","journal-title":"Transl Psychiatry"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1037\/a0017376","volume":"135","author":"Belsky J.","year":"2009","unstructured":"Belsky J.; Pluess M.; Beyond diathesis stress: Differential susceptibility to environmental influences. Psychol Bull  2009,135(6),885-908","journal-title":"Psychol Bull"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nature13595","volume":"511","author":"Ripke S.","year":"2014","unstructured":"Ripke S.; Neale B.M.; Corvin A.; Walters J.T.R.; Farh K.H.; Holmans P.A.; Biological insights from 108 Schizophrenia-associated genetic loci. Nature  2014,511(7510),421-427","journal-title":"Nature"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/nature08186","volume":"460","author":"Stefansson H.","year":"2009","unstructured":"Stefansson H.; Ophoff R.A.; Steinberg S.; Andreassen O.A.; Cichon S.; Rujescu D.; Werge T.; Pietil&#xE4;inen O.P.H.; Mors O.; Mortensen P.B.; Sigurdsson E.; Gustafsson O.; Nyegaard M.; Tuulio-Henriksson A.; Ingason A.; Hansen T.; Suvisaari J.; Lonnqvist J.; Paunio T.; B&#xF8;rglum A.D.; Hartmann A.; Fink-Jensen A.; Nordentoft M.; Hougaard D.; Norgaard-Pedersen B.; B&#xF6;ttcher Y.; Olesen J.; Breuer R.; M&#xF6;ller H.J.; Giegling I.; Rasmussen H.B.; Timm S.; Mattheisen M.; Bitter I.; R&#xE9;thelyi J.M.; Magnusdottir B.B.; Sigmundsson T.; Olason P.; Masson G.; Gulcher J.R.; Haraldsson M.; Fossdal R.; Thorgeirsson T.E.; Thorsteinsdottir U.; Ruggeri M.; Tosato S.; Franke B.; Strengman E.; Kiemeney L.A.; Melle I.; Djurovic S.; Abramova L.; Kaleda V.; Sanjuan J.; de Frutos R.; Bramon E.; Vassos E.; Fraser G.; Ettinger U.; Picchioni M.; Walker N.; Toulopoulou T.; Need A.C.; Ge D.; Yoon J.; Shianna K.V.; Freimer N.B.; Cantor R.M.; Murray R.; Kong A.; Golimbet V.; Carracedo A.; Arango C.; Costas J.; J&#xF6;nsson E.G.; Terenius L.; Agartz I.; Petursson H.; N&#xF6;then M.M.; Rietschel M.; Matthews P.M.; Muglia P.; Peltonen L.; St Clair D.; Goldstein D.B.; Stefansson K.; Collier D.A.; Common variants conferring risk of schizophrenia. Nature  2009,460(7256),744-747","journal-title":"Nature"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41588-018-0059-2","volume":"50","author":"Pardi&#xF1;as A.F.","year":"2018","unstructured":"Pardi&#xF1;as A.F.; Holmans P.; Pocklington A.J.; Escott-Price V.; Ripke S.; Carrera N.; Legge S.E.; Bishop S.; Cameron D.; Hamshere M.L.; Han J.; Hubbard L.; Lynham A.; Mantripragada K.; Rees E.; MacCabe J.H.; McCarroll S.A.; Baune B.T.; Breen G.; Byrne E.M.; Dannlowski U.; Eley T.C.; Hayward C.; Martin N.G.; McIntosh A.M.; Plomin R.; Porteous D.J.; Wray N.R.; Caballero A.; Geschwind D.H.; Huckins L.M.; Ruderfer D.M.; Santiago E.; Sklar P.; Stahl E.A.; Won H.; Agerbo E.; Als T.D.; Andreassen O.A.; B&#xE6;kvad-Hansen M.; Mortensen P.B.; Pedersen C.B.; B&#xF8;rglum A.D.; Bybjerg-Grauholm J.; Djurovic S.; Durmishi N.; Pedersen M.G.; Golimbet V.; Grove J.; Hougaard D.M.; Mattheisen M.; Molden E.; Mors O.; Nordentoft M.; Pejovic-Milovancevic M.; Sigurdsson E.; Silagadze T.; Hansen C.S.; Stefansson K.; Stefansson H.; Steinberg S.; Tosato S.; Werge T.; Collier D.A.; Rujescu D.; Kirov G.; Owen M.J.; O\u2019Donovan M.C.; Walters J.T.R.; Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat Genet  2018,50(3),381-389","journal-title":"Nat Genet"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1176\/appi.ajp.2013.13010086","volume":"171","author":"Benros M.E.","year":"2014","unstructured":"Benros M.E.; Pedersen M.G.; Rasmussen H.; Eaton W.W.; Nordentoft M.; Mortensen P.B.; A nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis. Am J Psychiatry  2014,171(2),218-226","journal-title":"Am J Psychiatry"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature16549","volume":"530","author":"Sekar A.","year":"2016","unstructured":"Sekar A.; Bialas A.R.; de Rivera H.; Davis A.; Hammond T.R.; Kamitaki N.; Tooley K.; Presumey J.; Baum M.; Van Doren V.; Genovese G.; Rose S.A.; Handsaker R.E.; Daly M.J.; Carroll M.C.; Stevens B.; McCarroll S.A.; Schizophrenia risk from complex variation of complement component 4. Nature  2016,530(7589),177-183","journal-title":"Nature"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1093\/hmg\/ddz145","volume":"28","author":"Pouget J.G.","year":"2019","unstructured":"Pouget J.G.; Han B.; Wu Y.; Mignot E.; Ollila H.M.; Barker J.; Spain S.; Dand N.; Trembath R.; Martin J.; Mayes M.D.; Bossini-Castillo L.; L&#xF3;pez-Isac E.; Jin Y.; Santorico S.A.; Spritz R.A.; Hakonarson H.; Polychronakos C.; Raychaudhuri S.; Knight J.; Cross-disorder analysis of schizophrenia and 19 immune-mediated diseases identifies shared genetic risk. Hum Mol Genet  2019,28(20),3498-3513","journal-title":"Hum Mol Genet"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.schres.2019.05.028","volume":"217","author":"van Mierlo H.C.","year":"2020","unstructured":"van Mierlo H.C.; Schot A.; Boks M.P.M.; de Witte L.D.; The association between schizophrenia and the immune system: Review of the evidence from unbiased \u2018omic-studies\u2019. Schizophr Res  2020,217,114-123","journal-title":"Schizophr Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/cei.13279","volume":"197","author":"Nutma E.","year":"2019","unstructured":"Nutma E.; Willison H.; Martino G.; Amor S.; Neuroimmunology: The past, present and future. Clin Exp Immunol  2019,197(3),278-293","journal-title":"Clin Exp Immunol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S2215-0366(17)30293-6","volume":"5","author":"Pollak T.A.","year":"2018","unstructured":"Pollak T.A.; Drndarski S.; Stone J.M.; David A.S.; McGuire P.; Abbott N.J.; The blood-brain barrier in psychosis. Lancet Psychiatry  2018,5(1),79-92","journal-title":"Lancet Psychiatry"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"e1075","DOI":"10.1038\/tp.2017.4","volume":"7","author":"van Kesteren C F M.G.","year":"2017","unstructured":"van Kesteren C F M.G.; Gremmels H.; de Witte L.D.; Hol E.M.; Van Gool A.R.; Falkai P.G.; Kahn R.S.; Sommer I.E.C.; Immune involvement in the pathogenesis of Schizophrenia: A meta-analysis on postmortem brain studies. Transl Psychiatry  2017,7(3),e1075","journal-title":"Transl Psychiatry"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/glia.23962","volume":"69","author":"Snijders G.J.L.J.","year":"2021","unstructured":"Snijders G.J.L.J.; Zuiden W.; Sneeboer M.A.M.; Berdenis van Berlekom A.; Geest A.T.; Schnieder T.; MacIntyre D.J.; Hol E.M.; Kahn R.S.; Witte L.D.; A loss of mature microglial markers without immune activation in Schizophrenia. Glia  2021,69(5),1251-1267","journal-title":"Glia"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/imm.12163","volume":"141","author":"Peferoen L.","year":"2014","unstructured":"Peferoen L.; Kipp M.; van der Valk P.; van Noort J.M.; Amor S.; Oligodendrocyte-microglia cross-talk in the central nervous system. Immunology  2014,141(3),302-313","journal-title":"Immunology"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nri2015","volume":"7","author":"Perry V.H.","year":"2007","unstructured":"Perry V.H.; Cunningham C.; Holmes C.; Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol  2007,7(2),161-167","journal-title":"Nat Rev Immunol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1126\/science.1202529","volume":"333","author":"Paolicelli R.C.","year":"2011","unstructured":"Paolicelli R.C.; Bolasco G.; Pagani F.; Maggi L.; Scianni M.; Panzanelli P.; Giustetto M.; Ferreira T.A.; Guiducci E.; Dumas L.; Ragozzino D.; Gross C.T.; Synaptic pruning by microglia is necessary for normal brain development. Science  2011,333(6048),1456-1458","journal-title":"Science"},{"key":"ref=18","doi-asserted-by":"publisher","author":"Akiyoshi R.","unstructured":"Akiyoshi R.; Wake H.; Kato D.; Horiuchi H.; Ono R.; Ikegami A.; Haruwaka K.; Omori T.; Tachibana Y.; Moorhouse A.J.; Nabekura J.; Microglia enhance synapse activity to promote local network synchronization. eNeuro, 2018, 5(5), ENEURO.0088-18.2018.","DOI":"10.1523\/ENEURO.0088-18.2018"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1126\/science.abb8587","volume":"370","author":"Bartels T.","year":"2020","unstructured":"Bartels T.; De Schepper S.; Hong S.; Microglia modulate neurodegeneration in Alzheimer\u2019s and Parkinson\u2019s diseases. Science  2020,370(6512),66-69","journal-title":"Science"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.nbd.2017.07.017","volume":"106","author":"Schaafsma W.","year":"2017","unstructured":"Schaafsma W.; Basterra L.B.; Jacobs S.; Brouwer N.; Meerlo P.; Schaafsma A.; Boddeke E.W.G.M.; Eggen B.J.L.; Maternal inflammation induces immune activation of fetal microglia and leads to disrupted microglia immune responses, behavior, and learning performance in adulthood. Neurobiol Dis  2017,106,291-300","journal-title":"Neurobiol Dis"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1126\/science.aad0314","volume":"351","author":"Choi G.B.","year":"2016","unstructured":"Choi G.B.; Yim Y.S.; Wong H.; Kim S.; Kim H.; Kim S.V.; Hoeffer C.A.; Littman D.R.; Huh J.R.; The maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring. Science  2016,351(6276),933-939","journal-title":"Science"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.it.2019.02.001","volume":"40","author":"Neher J.J.","year":"2019","unstructured":"Neher J.J.; Cunningham C.; Priming microglia for innate immune memory in the brain. Trends Immunol  2019,40(4),358-374","journal-title":"Trends Immunol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/mp.2009.82","volume":"14","author":"Lahiri D.K.","year":"2009","unstructured":"Lahiri D.K.; Maloney B.; Zawia N.H.; The LEARn model: An epigenetic explanation for idiopathic neurobiological diseases. Mol Psychiatry  2009,14(11),992-1003","journal-title":"Mol Psychiatry"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.neubiorev.2016.03.017","volume":"65","author":"Davis J.","year":"2016","unstructured":"Davis J.; Eyre H.; Jacka F.N.; Dodd S.; Dean O.; McEwen S.; Debnath M.; McGrath J.; Maes M.; Amminger P.; McGorry P.D.; Pantelis C.; Berk M.; A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis. Neurosci Biobehav Rev  2016,65,185-194","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1038\/s41593-019-0532-y","volume":"22","author":"Sankowski R.","year":"2019","unstructured":"Sankowski R.; B&#xF6;ttcher C.; Masuda T.; Geirsdottir L.; Sagar; Sindram, E.; Seredenina, T.; Muhs, A.; Scheiwe, C.; Shah, M.J.; Heiland, D.H.; Schnell, O.; Gr&#xFC;n, D.; Priller, J.; Prinz, M. Mapping microglia states in the human brain through the integration of high-dimensional techniques. Nat Neurosci  2019,22(12),2098-2110","journal-title":"Nat Neurosci"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.neuron.2021.01.027","volume":"109","author":"Safaiyan S.","year":"2021","unstructured":"Safaiyan S.; Besson-Girard S.; Kaya T.; Cantuti-Castelvetri L.; Liu L.; Ji H.; Schifferer M.; Gouna G.; Usifo F.; Kannaiyan N.; Fitzner D.; Xiang X.; Rossner M.J.; Brendel M.; Gokce O.; Simons M.; White matter aging drives microglial diversity. Neuron  2021,109(7),1100-1117.e10","journal-title":"Neuron"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/wps.20404","volume":"16","author":"Schultze-Lutter F.","year":"2017","unstructured":"Schultze-Lutter F.; Theodoridou A.; The concept of basic symptoms: Its scientific and clinical relevance. World Psychiatry  2017,16(1),104-105","journal-title":"World Psychiatry"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12974-016-0573-z","volume":"13","author":"Jiang L.","year":"2016","unstructured":"Jiang L.; Wu X.; Wang S.; Chen S.H.; Zhou H.; Wilson B.; Jin C.Y.; Lu R.B.; Xie K.; Wang Q.; Hong J.S.; Clozapine metabolites protect dopaminergic neurons through inhibition of microglial NADPH oxidase. J Neuroinflammation  2016,13(1),110","journal-title":"J Neuroinflammation"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s12974-018-1385-0","volume":"15","author":"Shaerzadeh F.","year":"2018","unstructured":"Shaerzadeh F.; Streit W.J.; Heysieattalab S.; Khoshbouei H.; Methamphetamine neurotoxicity, microglia, and neuroinflammation. J Neuroinflammation  2018,15(1),341","journal-title":"J Neuroinflammation"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.schres.2013.10.040","volume":"151","author":"Ribeiro B.M.M.","year":"2013","unstructured":"Ribeiro B.M.M.; do Carmo M.R.S.; Freire R.S.; Rocha N.F.M.; Borella V.C.M.; de Menezes A.T.; Monte A.S.; Gomes P.X.L.; de Sousa F.C.F.; Vale M.L.; de Lucena D.F.; Gama C.S.; Mac&#xEA;do D.; Evidences for a progressive microglial activation and increase in iNOS expression in rats submitted to a neurodevelopmental model of schizophrenia: Reversal by clozapine. Schizophr Res  2013,151(1-3),12-19","journal-title":"Schizophr Res"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/schbul\/sbp116","volume":"36","author":"Buchanan R.W.","year":"2010","unstructured":"Buchanan R.W.; Kreyenbuhl J.; Kelly D.L.; Noel J.M.; Boggs D.L.; Fischer B.A.; Himelhoch S.; Fang B.; Peterson E.; Aquino P.R.; Keller W.; The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull  2010,36(1),71-93","journal-title":"Schizophr Bull"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/acps.13111","volume":"141","author":"Rubio J.M.","year":"2020","unstructured":"Rubio J.M.; Kane J.M.; How and when to use clozapine. Acta Psychiatr Scand  2020,141(3),178-189","journal-title":"Acta Psychiatr Scand"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/YIC.0000000000000086","volume":"30","author":"&#xDC;&#xE7;ok A.","year":"2015","unstructured":"&#xDC;&#xE7;ok A.; &#xC7;ikrik&#xE7;ili U.; Karabulut S.; Salaj A.; &#xD6;zt&#xFC;rk M.; Tabak &#xD6;.; Durak R.; Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia. Int Clin Psychopharmacol  2015,30(5),290-295","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/bs.apha.2017.09.009","volume":"82","author":"Khokhar J.Y.","year":"2018","unstructured":"Khokhar J.Y.; Henricks A.M.; Sullivan E.D.K.; Green A.I.; Unique effects of clozapine: A pharmacological perspective. Adv Pharmacol  2018,82,137-162","journal-title":"Adv Pharmacol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1021\/cn400121z","volume":"4","author":"Wenthur C.J.","year":"2013","unstructured":"Wenthur C.J.; Lindsley C.W.; Classics in chemical neuroscience. Clozapine ACS Chem Neurosci  2013,4(7),1018-1025","journal-title":"Clozapine ACS Chem Neurosci"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/psp4.38","volume":"4","author":"Park H.S.","year":"2015","unstructured":"Park H.S.; Kim E.; Moon B.S.; Lim N.H.; Lee B.C.; Kim S.E.; In vivo tissue pharmacokinetics of carbon-11-labeled clozapine in healthy volunteers: A positron emission tomography study. CPT Pharmacometrics Syst Pharmacol  2015,4(5),305-311","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"656941","DOI":"10.3389\/fimmu.2021.656941","volume":"12","author":"Ceylan U.","year":"2021","unstructured":"Ceylan U.; Haupeltshofer S.; K&#xE4;mper L.; Dann J.; Ambrosius B.; Gold R.; Faissner S.; Clozapine regulates microglia and is effective in chronic experimental autoimmune encephalomyelitis. Front Immunol  2021,12,656941","journal-title":"Front Immunol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/j.1476-5381.2011.01302.x","volume":"164","author":"Constantinescu C.S.","year":"2011","unstructured":"Constantinescu C.S.; Farooqi N.; O\u2019Brien K.; Gran B.; Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol  2011,164(4),1079-1106","journal-title":"Br J Pharmacol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"103522","DOI":"10.1016\/j.msard.2022.103522","volume":"58","year":"2022","unstructured":"Stamoula, \u0395 Ainatzoglou, A.; Stamatellos, V.P.; Dardalas, I.; Siafis, S.; Matsas, A.; Stamoulas, K.; Papazisis, G. Atypical antipsychotics in multiple sclerosis: A review of their in vivo immunomodulatory effects. Mult Scler Relat Disord  2022,58,103522","journal-title":"Mult Scler Relat Disord"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12974-020-01733-4","volume":"17","author":"Robichon K.","year":"2020","unstructured":"Robichon K.; Patel V.; Connor B.; La Flamme A.C.; Clozapine reduces infiltration into the CNS by targeting migration in experimental autoimmune encephalomyelitis. J Neuroinflammation  2020,17(1),53","journal-title":"J Neuroinflammation"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1038\/s41598-021-82667-6","volume":"11","author":"Robichon K.","year":"2021","unstructured":"Robichon K.; Sondhauss S.; Jordan T.W.; Keyzers R.A.; Connor B.; La Flamme A.C.; Localisation of clozapine during experimental autoimmune encephalomyelitis and its impact on dopamine and its receptors. Sci Rep  2021,11(1),2966","journal-title":"Sci Rep"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"2055217317698724","DOI":"10.1177\/2055217317698724","volume":"3","author":"Green L.K.","year":"2017","unstructured":"Green L.K.; Zareie P.; Templeton N.; Keyzers R.A.; Connor B.; La Flamme A.C.; Enhanced disease reduction using clozapine, an atypical antipsychotic agent, and glatiramer acetate combination therapy in experimental autoimmune encephalomyelitis. Mult Scler J Exp Transl Clin  2017,3(1),2055217317698724","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.pnpbp.2012.11.007","volume":"42","author":"Dodd S.","year":"2013","unstructured":"Dodd S.; Maes M.; Anderson G.; Dean O.M.; Moylan S.; Berk M.; Putative neuroprotective agents in neuropsychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry  2013,42,135-145","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1017\/S1461145711001775","volume":"16","author":"MacDowell K.S.","year":"2013","unstructured":"MacDowell K.S.; Garc&#xED;a-Bueno B.; Madrigal J.L.M.; Parellada M.; Arango C.; Mic&#xF3; J.A.; Leza J.C.; Risperidone normalizes increased inflammatory parameters and restores anti-inflammatory pathways in a model of neuroinflammation. Int J Neuropsychopharmacol  2013,16(1),121-135","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/sj.npp.1300911","volume":"31","author":"Basta-Kaim A.","year":"2006","unstructured":"Basta-Kaim A.; Budziszewska B.; Jaworska-Feil L.; Tetich M.; Kubera M.; Le&#x15B;kiewicz, M.; Otczyk, M.; Laso\u0144, W. Antipsychotic drugs inhibit the human corticotropin-releasing-hormone gene promoter activity in neuro-2A cells-an involvement of protein kinases. Neuropsychopharmacology  2006,31(4),853-865","journal-title":"Neuropsychopharmacology"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.schres.2007.01.019","volume":"92","author":"Kato T.","year":"2007","unstructured":"Kato T.; Monji A.; Hashioka S.; Kanba S.; Risperidone significantly inhibits interferon-&#x3B3;-induced microglial activation in vitro. Schizophr Res  2007,92(1-3),108-115","journal-title":"Schizophr Res"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.pnpbp.2008.12.006","volume":"33","author":"Sugino H.","year":"2009","unstructured":"Sugino H.; Futamura T.; Mitsumoto Y.; Maeda K.; Marunaka Y.; Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice. Prog Neuropsychopharmacol Biol Psychiatry  2009,33(2),303-307","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejphar.2015.03.003","volume":"755","author":"Shin H.","year":"2015","unstructured":"Shin H.; Kim J.; Song J.H.; Clozapine and olanzapine inhibit proton currents in BV2 microglial cells. Eur J Pharmacol  2015,755,74-79","journal-title":"Eur J Pharmacol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.3390\/ijms22094399","volume":"22","author":"Racki V.","year":"2021","unstructured":"Racki V.; Marcelic M.; Stimac I.; Petric D.; Kucic N.; Effects of haloperidol, risperidone, and aripiprazole on the immunometabolic properties of BV-2 microglial cells. Int J Mol Sci  2021,22(9),4399","journal-title":"Int J Mol Sci"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"pyu022","DOI":"10.1093\/ijnp\/pyu022","volume":"18","author":"Zhu S.","year":"2015","unstructured":"Zhu S.; Shi R.; Li V.; Wang J.; Zhang R.; Tempier A.; He J.; Kong J.; Wang J-F.; Li X-M.; Quetiapine attenuates glial activation and proinflammatory cytokines in APP\/PS1 transgenic mice via inhibition of nuclear factor- b pathway. Int J Neuropsychopharmacol  2015,18(3),pyu022","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3389\/fncel.2015.00492","volume":"9","author":"Wang H.","year":"2015","unstructured":"Wang H.; Liu S.; Tian Y.; Wu X.; He Y.; Li C.; Namaka M.; Kong J.; Li H.; Xiao L.; Quetiapine inhibits microglial activation by neutralizing abnormal STIM1-mediated intercellular calcium homeostasis and promotes myelin repair in a cuprizone-induced mouse model of demyelination. Front Cell Neurosci  2015,9,492","journal-title":"Front Cell Neurosci"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.3390\/jcm10112488","volume":"10","author":"Marcinowicz P.","year":"2021","unstructured":"Marcinowicz P.; Wi\u0119d\u0142ocha, M.; Zborowska, N.; D\u0119bowska, W.; Podwalski, P.; Misiak, B.; Tyburski, E.; Szulc, A. A meta-analysis of the influence of antipsychotics on cytokines levels in first episode psychosis. J Clin Med  2021,10(11),2488","journal-title":"J Clin Med"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.schres.2013.10.011","volume":"151","author":"Tourjman V.","year":"2013","unstructured":"Tourjman V.; Kouassi &#xC9;.; Kou&#xE9; M.&#xC8;.; Rocchetti M.; Fortin-Fournier S.; Fusar-Poli P.; Potvin S.; Antipsychotics\u2019 effects on blood levels of cytokines in schizophrenia: A meta-analysis. Schizophr Res  2013,151(1-3),43-47","journal-title":"Schizophr Res"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1093\/ijnp\/pyy062","volume":"21","author":"Romeo B.","year":"2018","unstructured":"Romeo B.; Brunet-Lecomte M.; Martelli C.; Benyamina A.; Kinetics of cytokine levels during antipsychotic treatment in schizophrenia: A meta-analysis. Int J Neuropsychopharmacol  2018,21(9),828-836","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.neubiorev.2017.03.003","volume":"77","author":"Capuzzi E.","year":"2017","unstructured":"Capuzzi E.; Bartoli F.; Crocamo C.; Clerici M.; Carr&#xE0; G.; Acute variations of cytokine levels after antipsychotic treatment in drug-na&#xEF;ve subjects with a first-episode psychosis: A meta-analysis. Neurosci Biobehav Rev  2017,77,122-128","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/mp.2016.3","volume":"21","author":"Goldsmith D.R.","year":"2016","unstructured":"Goldsmith D.R.; Rapaport M.H.; Miller B.J.; A meta-analysis of blood cytokine network alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry  2016,21(12),1696-1709","journal-title":"Mol Psychiatry"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","volume":"70","author":"Miller B.J.","year":"2011","unstructured":"Miller B.J.; Buckley P.; Seabolt W.; Mellor A.; Kirkpatrick B.; Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects. Biol Psychiatry  2011,70(7),663-671","journal-title":"Biol Psychiatry"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/ijnp\/pyx015","volume":"20","author":"Fraguas D.","year":"2017","unstructured":"Fraguas D.; D&#xED;az-Caneja C.M.; Rodr&#xED;guez-Quiroga A.; Arango C.; Oxidative stress and inflammation in early onset first episode psychosis: A systematic review and meta-analysis. Int J Neuropsychopharmacol  2017,20(6),435-444","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=59","doi-asserted-by":"publisher","DOI":"10.1177\/00368504211054985","volume":"104","author":"Ishijima T.","year":"2021","unstructured":"Ishijima T.; Nakajima K.; Inflammatory cytokines TNF&#x3B1; IL-1&#x3B2; and IL-6 are induced in endotoxin- stimulated microglia through different signaling cascades. Sci Prog  2021,104(4)","journal-title":"Sci Prog"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1089\/cap.2015.0220","volume":"26","author":"&#x15E;im&#x15F;ek &#x15E;.","year":"2016","unstructured":"&#x15E;im&#x15F;ek &#x15E;.; Y\u0131ld\u0131r\u0131m V.; &#xC7;im A.; Kaya S.; Serum IL-4 and IL-10 levels correlate with the symptoms of the drug-naive adolescents\nwith first episode, early onset schizophrenia. J. Child Adolesc. Psychopharmacol.,  2016,26(8),721-726"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"pyu042","DOI":"10.1093\/ijnp\/pyu042","volume":"18","author":"Noto C.","year":"2015","unstructured":"Noto C.; Ota V.K.; Gouvea E.S.; Rizzo L.B.; Spindola L.M.N.; Honda P.H.S.; Cordeiro Q.; Belangero S.I.; Bressan R.A.; Gadelha A.; Maes M.; Brietzke E.; Effects of risperidone on cytokine profile in drug-na&#xEF;ve first-episode psychosis. Int J Neuropsychopharmacol  2015,18(4),pyu042-pyu042","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"e777","DOI":"10.1038\/tp.2016.40","volume":"6","author":"Coughlin J.M.","year":"2016","unstructured":"Coughlin J.M.; Wang Y.; Ambinder E.B.; Ward R.E.; Minn I.; Vranesic M.; Kim P.K.; Ford C.N.; Higgs C.; Hayes L.N.; Schretlen D.J.; Dannals R.F.; Kassiou M.; Sawa A.; Pomper M.G.; In vivo markers of inflammatory response in recent-onset schizophrenia: A combined study using [11C]DPA-713 PET and analysis of CSF and plasma. Transl Psychiatry  2016,6(4),e777-e777","journal-title":"Transl Psychiatry"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2174\/138955711795906941","volume":"11","author":"Kato T.A.","year":"2011","unstructured":"Kato T.A.; Monji A.; Mizoguchi Y.; Hashioka S.; Horikawa H.; Seki Y.; Kasai M.; Utsumi H.; Kanba S.; Anti-Inflammatory properties of antipsychotics via microglia modulations: Are antipsychotics a \u2018fire extinguisher\u2019 in the brain of Schizophrenia? Mini Rev Med Chem  2011,11(7),565-574","journal-title":"Mini Rev Med Chem"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40263-020-00765-x","volume":"34","author":"Dinesh A.A.","year":"2020","unstructured":"Dinesh A.A.; Islam J.; Khan J.; Turkheimer F.; Vernon A.C.; Effects of antipsychotic drugs: Cross talk between the nervous and innate immune system. CNS Drugs  2020,34(12),1229-1251","journal-title":"CNS Drugs"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.mcn.2005.01.003","volume":"29","author":"F&#xE4;rber K.","year":"2005","unstructured":"F&#xE4;rber K.; Pannasch U.; Kettenmann H.; Dopamine and noradrenaline control distinct functions in rodent microglial cells. Mol Cell Neurosci  2005,29(1),128-138","journal-title":"Mol Cell Neurosci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/j.1471-4159.2008.05435.x","volume":"106","author":"Kato T.","year":"2008","unstructured":"Kato T.; Mizoguchi Y.; Monji A.; Horikawa H.; Suzuki S.O.; Seki Y.; Iwaki T.; Hashioka S.; Kanba S.; Inhibitory effects of aripiprazole on interferon--induced microglial activation via intracellular Ca 2+ regulation in vitro. J Neurochem  2008,106(2),815-825","journal-title":"J Neurochem"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"e104430","DOI":"10.1371\/journal.pone.0104430","volume":"9","author":"O\u2019Sullivan D.","year":"2014","unstructured":"O\u2019Sullivan D.; Green L.; Stone S.; Zareie P.; Kharkrang M.; Fong D.; Connor B.; La Flamme A.C.; Treatment with the antipsychotic agent, risperidone, reduces disease severity in experimental autoimmune encephalomyelitis. PLoS One  2014,9(8),e104430","journal-title":"PLoS One"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.3389\/fphar.2020.01003","volume":"11","author":"Martel J.C.","year":"2020","unstructured":"Martel J.C.; Gatti McArthur S.; Dopamine receptor subtypes, physiology and pharmacology: New ligands and concepts in schizophrenia. Front Pharmacol  2020,11,1003","journal-title":"Front Pharmacol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jneuroim.2005.07.013","volume":"169","author":"Besser M.J.","year":"2005","unstructured":"Besser M.J.; Ganor Y.; Levite M.; Dopamine by itself activates either D2, D3 or D1\/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNF&#x3B1; or both. J Neuroimmunol  2005,169(1-2),161-171","journal-title":"J Neuroimmunol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.coph.2008.05.001","volume":"8","author":"Levite M.","year":"2008","unstructured":"Levite M.; Neurotransmitters activate T-cells and elicit crucial functions via neurotransmitter receptors. Curr Opin Pharmacol  2008,8(4),460-471","journal-title":"Curr Opin Pharmacol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/3160486","volume":"2016","author":"Arreola R.","year":"2016","unstructured":"Arreola R.; Alvarez-Herrera S.; P&#xE9;rez-S&#xE1;nchez G.; Becerril-Villanueva E.; Cruz-Fuentes C.; Flores-Gutierrez E.O.; Garc&#xE9;s-Alvarez M.E.; de la Cruz-Aguilera D.L.; Medina-Rivero E.; Hurtado-Alvarado G.; Quintero-Fabi&#xE1;n S.; Pav&#xF3;n L.; Immunomodulatory effects mediated by dopamine. J Immunol Res  2016,2016,1-31","journal-title":"J Immunol Res"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3389\/fphar.2020.00394","volume":"11","author":"Vidal P.M.","year":"2020","unstructured":"Vidal P.M.; Pacheco R.; The cross-talk between the dopaminergic and the immune system involved in schizophrenia. Front Pharmacol  2020,11,394","journal-title":"Front Pharmacol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.pnpbp.2017.04.012","volume":"81","author":"Jeon S.","year":"2018","unstructured":"Jeon S.; Kim S.H.; Shin S.Y.; Lee Y.H.; Clozapine reduces toll-like receptor 4\/NF-&#x3BA;B-mediated inflammatory responses through inhibition of calcium\/calmodulin-dependent Akt activation in microglia. Prog Neuropsychopharmacol Biol Psychiatry  2018,81,477-487","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/j.cellsig.2006.02.004","volume":"18","author":"Shin S.Y.","year":"2006","unstructured":"Shin S.Y.; Choi B.H.; Ko J.; Kim S.H.; Kim Y.S.; Lee Y.H.; Clozapine, a neuroleptic agent, inhibits Akt by counteracting Ca2+\/calmodulin in PTEN-negative U-87MG human glioblastoma cells. Cell Signal  2006,18(11),1876-1886","journal-title":"Cell Signal"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.brainres.2012.06.032","volume":"1470","author":"Zheng W.","year":"2012","unstructured":"Zheng W.; Wang H.; Zeng Z.; Lin J.; Little P.J.; Srivastava L.K.; Quirion R.; The possible role of the Akt signaling pathway in schizophrenia. Brain Res  2012,1470,145-158","journal-title":"Brain Res"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"7612172","DOI":"10.1155\/2018\/7612172","volume":"2018","author":"Chen P.","year":"2018","unstructured":"Chen P.; Bornhorst J.; Neely M.D.; Avila D.S.; Mechanisms and disease pathogenesis underlying metal-induced oxidative stress. Oxid Med Cell Longev  2018,2018,7612172","journal-title":"Oxid Med Cell Longev"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3390\/cells9030577","volume":"9","author":"Giridharan V.V.","year":"2020","unstructured":"Giridharan V.V.; Scaini G.; Colpo G.D.; Doifode T.; Pinjari O.F.; Teixeira A.L.; Petronilho F.; Mac&#xEA;do D.; Quevedo J.; Barichello T.; Clozapine prevents poly (I:C) induced inflammation by modulating NLRP3 pathway in microglial cells. Cells  2020,9(3),577","journal-title":"Cells"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.schres.2016.08.022","volume":"178","author":"Sato-Kasai M.","year":"2016","unstructured":"Sato-Kasai M.; Kato T.A.; Ohgidani M.; Mizoguchi Y.; Sagata N.; Inamine S.; Horikawa H.; Hayakawa K.; Shimokawa N.; Kyuragi S.; Seki Y.; Monji A.; Kanba S.; Aripiprazole inhibits polyI:C-induced microglial activation possibly via TRPM7. Schizophr Res  2016,178(1-3),35-43","journal-title":"Schizophr Res"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.neuropharm.2011.01.009","volume":"62","author":"Meyer U.","year":"2012","unstructured":"Meyer U.; Feldon J.; To poly(I:C) or not to poly(I:C): Advancing preclinical schizophrenia research through the use of prenatal immune activation models. Neuropharmacology  2012,62(3),1308-1321","journal-title":"Neuropharmacology"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3389\/fnins.2018.00203","volume":"12","author":"Yuen J.W.Y.","year":"2018","unstructured":"Yuen J.W.Y.; Kim D.D.; Procyshyn R.M.; White R.F.; Honer W.G.; Barr A.M.; Clozapine-induced cardiovascular side effects and autonomic dysfunction: A systematic review. Front Neurosci  2018,12,203","journal-title":"Front Neurosci"},{"key":"ref=81","author":"Yuen J.W.Y.","year":"2021","unstructured":"Yuen J.W.Y.; Kim D.D.; Procyshyn R.M.; Panenka W.J.; Honer W.G.; Barr A.M.;  A focused review of the metabolic side-effects of clozapineFront Endocrinol  2021","journal-title":"A focused review of the metabolic side-effects of clozapineFront Endocrinol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/MOH.0000000000000391","volume":"25","year":"2018","unstructured":"Wici\u0144ski, M.; W\u0119clewicz, M.M. Clozapine-induced agranulocytosis\/granulocytopenia. Curr Opin Hematol  2018,25(1),22-28","journal-title":"Curr Opin Hematol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/tpj.2017.6","volume":"17","author":"de With S A J.","year":"2017","unstructured":"de With S A J.; Pulit S.L.; Staal W.G.; Kahn R.S.; Ophoff R.A.; More than 25 years of genetic studies of clozapine-induced agranulocytosis. Pharmacogenomics J  2017,17(4),304-311","journal-title":"Pharmacogenomics J"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1017\/S0033291719000369","volume":"50","author":"Li X.H.","year":"2020","unstructured":"Li X.H.; Zhong X.M.; Lu L.; Zheng W.; Wang S.; Rao W.; Wang S.; Ng C.H.; Ungvari G.S.; Wang G.; Xiang Y.T.; The prevalence of agranulocytosis and related death in clozapine-treated patients: A comprehensive meta-analysis of observational studies. Psychol Med  2020,50(4),583-594","journal-title":"Psychol Med"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/S0140-6736(99)03111-6","volume":"354","author":"Naumann R.","year":"1999","unstructured":"Naumann R.; Felber W.; Heilemann H.; Reuster T.; Olanzapine-induced agranulocytosis. Lancet  1999,354(9178),566-567","journal-title":"Lancet"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1021\/tx500183x","volume":"27","author":"Ng W.","year":"2014","unstructured":"Ng W.; Kennar R.; Uetrecht J.; Effect of clozapine and olanzapine on neutrophil kinetics: implications for drug-induced agranulocytosis. Chem Res Toxicol  2014,27(7),1104-1108","journal-title":"Chem Res Toxicol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41398-021-01470-z","volume":"11","author":"Chen J.","year":"2021","unstructured":"Chen J.; Yang P.; Zhang Q.; Chen R.; Wang P.; Liu B.; Sun W.; Jian X.; Xiang S.; Zhou J.; Li N.; Wang K.; Gao C.; Wen Y.; Wu C.; Zhang J.; Zhao Y.; Yang Q.; Li M.; Stewart R.; Sun Y.; Pan D.; Niu Y.; Wang Z.; Xu Y.; Li X.; He L.; Li Z.; Shi Y.; Genetic risk of clozapine-induced leukopenia and neutropenia: A genome-wide association study. Transl Psychiatry  2021,11(1),343","journal-title":"Transl Psychiatry"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/tpj.2016.32","volume":"17","author":"van der Weide K.","year":"2017","unstructured":"van der Weide K.; Loovers H.; Pondman K.; Bogers J.; van der Straaten T.; Langemeijer E.; Cohen D.; Commandeur J.; van der Weide J.; Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population. Pharmacogenomics J  2017,17(5),471-478","journal-title":"Pharmacogenomics J"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41398-021-01322-w","volume":"11","author":"Konte B.","year":"2021","unstructured":"Konte B.; Walters J.T.R.; Rujescu D.; Legge S.E.; Pardi&#xF1;as A.F.; Cohen D.; Pirmohamed M.; Tiihonen J.; Hartmann A.M.; Bogers J.P.; van der Weide J.; van der Weide K.; Putkonen A.; Repo-Tiihonen E.; Hallikainen T.; Silva E.; Ingimarsson O.; Sigurdsson E.; Kennedy J.L.; Sullivan P.F.; Rietschel M.; Breen G.; Stefansson H.; Stefansson K.; Collier D.A.; O\u2019Donovan M.C.; Giegling I.; HLA-DQB1 6672G>C (rs113332494) is associated with clozapine-induced neutropenia and agranulocytosis in individuals of European ancestry. Transl Psychiatry  2021,11(1),214","journal-title":"Transl Psychiatry"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3389\/fphar.2018.01049","volume":"9","author":"Numata S.","year":"2018","unstructured":"Numata S.; Umehara H.; Ohmori T.; Hashimoto R.; Clozapine pharmacogenetic studies in schizophrenia: Efficacy and agranulocytosis. Front Pharmacol  2018,9,1049","journal-title":"Front Pharmacol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/j.1365-2141.1994.tb04786.x","volume":"86","author":"Gerson S.L.","year":"1994","unstructured":"Gerson S.L.; Arce C.; Meltzer H.Y.; N-desmethylclozapine: A clozapine metabolite that suppresses haemopoiesis. Br J Haematol  1994,86(3),555-561","journal-title":"Br J Haematol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s00044-015-1484-8","volume":"25","author":"Borges R.S.","year":"2016","unstructured":"Borges R.S.; Nagurniak G.R.; Queiroz L.M.D.; Maia C.S.F.; Barros C.A.L.; Orestes E.; da Silva A.B.F.; Structure and toxicity of clozapine and olanzapine on agranulocytosis. Med Chem Res  2016,25(2),322-328","journal-title":"Med Chem Res"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1111\/bph.13425","volume":"174","author":"Haslund-Vinding J.","year":"2017","unstructured":"Haslund-Vinding J.; McBean G.; Jaquet V.; Vilhardt F.; NADPH oxidases in oxidant production by microglia: activating receptors, pharmacology and association with disease. Br J Pharmacol  2017,174(12),1733-1749","journal-title":"Br J Pharmacol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1055\/s-2007-979495","volume":"30","author":"Pollm&#xE4;cher T.","year":"1997","unstructured":"Pollm&#xE4;cher T.; Fenzel T.; Mullington J.; Hinze-Selch D.; The influence of clozapine treatment on plasma granulocyte colony-stimulating (G-CSF) levels. Pharmacopsychiatry  1997,30(4),118-121","journal-title":"Pharmacopsychiatry"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1021\/tx500184c","volume":"27","author":"Lobach A.R.","year":"2014","unstructured":"Lobach A.R.; Uetrecht J.; Clozapine promotes the proliferation of granulocyte progenitors in the bone marrow leading to increased granulopoiesis and neutrophilia in rats. Chem Res Toxicol  2014,27(7),1109-1119","journal-title":"Chem Res Toxicol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/JCP.0b013e3181eeb7f7","volume":"30","author":"L&#xF6;ffler S.","year":"2010","unstructured":"L&#xF6;ffler S.; Klimke A.; Kronenwett R.; Kobbe G.; Haas R.; Fehsel K.; Clozapine mobilizes CD34+ hematopoietic stem and progenitor cells and increases plasma concentration of interleukin 6 in patients with schizophrenia. J Clin Psychopharmacol  2010,30(5),591-595","journal-title":"J Clin Psychopharmacol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1177\/026988110101500306","volume":"15","author":"Delieu J.M.","year":"2001","unstructured":"Delieu J.M.; Badawoud M.; Williams M.A.; Horobin R.W.; Duguid J.K.; Antipsychotic drugs result in the formation of immature neutrophil leucocytes in Schizophrenic patients. J Psychopharmacol  2001,15(3),191-194","journal-title":"J Psychopharmacol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/sj.leu.2400607","volume":"11","author":"Spiekermann K.","year":"1997","unstructured":"Spiekermann K.; Roesler J.; Emmendoerffer A.; Elsner J.; Welte K.; Functional features of neutrophils induced by G-CSF and GM-CSF treatment: Differential effects and clinical implications. Leukemia  1997,11(4),466-478","journal-title":"Leukemia"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1021\/tx100035k","volume":"23","author":"Iverson S.","year":"2010","unstructured":"Iverson S.; Kautiainen A.; Ip J.; Uetrecht J.P.; Effect of clozapine on neutrophil kinetics in rabbits. Chem Res Toxicol  2010,23(7),1184-1191","journal-title":"Chem Res Toxicol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/0165-5728(90)90094-4","volume":"30","author":"Suzumura A.","year":"1990","unstructured":"Suzumura A.; Sawada M.; Yamamoto H.; Marunouchi T.; Effects of colony stimulating factors on isolated microglia in vitro. J Neuroimmunol  1990,30(2-3),111-120","journal-title":"J Neuroimmunol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1007\/s12026-017-8928-9","volume":"65","author":"Peng W.","year":"2017","unstructured":"Peng W.; RETRACTED ARTICLE: Neuroprotective effects of G-CSF administration in microglia-mediated reactive T cell activation in vitro. Immunol Res  2017,65(4),888-902","journal-title":"Immunol Res"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12974-020-01903-4","volume":"17","author":"Dikmen H.O.","year":"2020","unstructured":"Dikmen H.O.; Hemmerich M.; Lewen A.; Hollnagel J.O.; Chausse B.; Kann O.; GM-CSF induces noninflammatory proliferation of microglia and disturbs electrical neuronal network rhythms in situ. J Neuroinflammation  2020,17(1),235","journal-title":"J Neuroinflammation"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.2174\/138955708786786453","volume":"8","author":"Fedi V.","year":"2008","unstructured":"Fedi V.; Guidi A.; Altamura M.; Tricyclic structures in medicinal chemistry: An overview of their recent uses in non-CNS pathologies. Mini Rev Med Chem  2008,8(14),1464-1484","journal-title":"Mini Rev Med Chem"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1080\/17512433.2020.1787831","volume":"13","author":"de Filippis R.","year":"2020","unstructured":"de Filippis R.; Soldevila-Mat&#xED;as P.; De Fazio P.; Guinart D.; Fuentes-Dur&#xE1; I.; Rubio J.M.; Kane J.M.; Schoretsanitis G.; Clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: A systematic review. Expert Rev Clin Pharmacol  2020,13(8),875-883","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1055\/s-0042-103159","volume":"49","author":"Eyre H.","year":"2016","unstructured":"Eyre H.; Lavretsky H.; Kartika J.; Qassim A.; Baune B.; Modulatory effects of antidepressant classes on the innate and adaptive immune system in depression. Pharmacopsychiatry  2016,49(3),85-96","journal-title":"Pharmacopsychiatry"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00005-019-00543-8","volume":"67","year":"2019","unstructured":"Sza\u0142ach, \u0141.P.; Lisowska, K.A.; Cuba\u0142a, W.J. The influence of antidepressants on the immune system. Arch Immunol Ther Exp  2019,67(3),143-151","journal-title":"Arch Immunol Ther Exp"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1021\/jm00120a002","volume":"31","author":"Evans B.E.","year":"1988","unstructured":"Evans B.E.; Rittle K.E.; Bock M.G.; DiPardo R.M.; Freidinger R.M.; Whitter W.L.; Lundell G.F.; Veber D.F.; Anderson P.S.; Chang R.S.L.; Lotti V.J.; Cerino D.J.; Chen T.B.; Kling P.J.; Kunkel K.A.; Springer J.P.; Hirshfield J.; Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem  1988,31(12),2235-2246","journal-title":"J Med Chem"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1017\/S0033291719001995","volume":"49","author":"&#xC7;akici N.","year":"2019","unstructured":"&#xC7;akici N.; van Beveren N.J.M.; Judge-Hundal G.; Koola M.M.; Sommer I.E.C.; An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: A meta-analysis. Psychol Med  2019,49(14),2307-2319","journal-title":"Psychol Med"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/schbul\/sbt139","volume":"40","author":"Sommer I.E.","year":"2014","unstructured":"Sommer I.E.; van Westrhenen R.; Begemann M.J.H.; de Witte L.D.; Leucht S.; Kahn R.S.; Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: An update. Schizophr Bull  2014,40(1),181-191","journal-title":"Schizophr Bull"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/frne.1999.0188","volume":"21","author":"Compagnone N.A.","year":"2000","unstructured":"Compagnone N.A.; Mellon S.H.; Neurosteroids: Biosynthesis and function of these novel neuromodulators. Front Neuroendocrinol  2000,21(1),1-56","journal-title":"Front Neuroendocrinol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1043-2760(01)00503-3","volume":"13","author":"Mellon S.H.","year":"2002","unstructured":"Mellon S.H.; Griffin L.D.; Neurosteroids: Biochemistry and clinical significance. Trends Endocrinol Metab  2002,13(1),35-43","journal-title":"Trends Endocrinol Metab"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"100788","DOI":"10.1016\/j.yfrne.2019.100788","volume":"55","author":"Yilmaz C.","year":"2019","unstructured":"Yilmaz C.; Karali K.; Fodelianaki G.; Gravanis A.; Chavakis T.; Charalampopoulos I.; Alexaki V.I.; Neurosteroids as regulators of neuroinflammation. Front Neuroendocrinol  2019,55,100788","journal-title":"Front Neuroendocrinol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pneurobio.2003.09.004","volume":"71","author":"Schumacher M.","year":"2003","unstructured":"Schumacher M.; Weill-Engerer S.; Liere P.; Robert F.; Franklin R.J.M.; Garcia-Segura L.M.; Lambert J.J.; Mayo W.; Melcangi R.C.; Parducz A.; Suter U.; Carelli C.; Baulieu E.E.; Akwa Y.; Steroid hormones and neurosteroids in normal and pathological aging of the nervous system. Prog Neurobiol  2003,71(1),3-29","journal-title":"Prog Neurobiol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jsbmb.2014.03.008","volume":"145","author":"St&#xE1;rka L.","year":"2015","unstructured":"St&#xE1;rka L.; Du\u0161kov&#xE1; M.; Hill M.; Dehydroepiandrosterone: A neuroactive steroid. J Steroid Biochem Mol Biol  2015,145,254-260","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1196\/annals.1366.003","volume":"1088","author":"Charalampopoulos I.","year":"2006","unstructured":"Charalampopoulos I.; Alexaki V.I.; Tsatsanis C.; Minas V.; Dermitzaki E.; Lasaridis I.; Vardouli L.; Stournaras C.; Margioris A.N.; Castanas E.; Gravanis A.; Neurosteroids as endogenous inhibitors of neuronal cell apoptosis in aging. Ann N Y Acad Sci  2006,1088(1),139-152","journal-title":"Ann N Y Acad Sci"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.tem.2008.07.004","volume":"19","author":"Charalampopoulos I.","year":"2008","unstructured":"Charalampopoulos I.; Remboutsika E.; Margioris A.N.; Gravanis A.; Neurosteroids as modulators of neurogenesis and neuronal survival. Trends Endocrinol Metab  2008,19(8),300-307","journal-title":"Trends Endocrinol Metab"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/mp.2017.167","volume":"23","author":"Alexaki V.I.","year":"2018","unstructured":"Alexaki V.I.; Fodelianaki G.; Neuwirth A.; Mund C.; Kourgiantaki A.; Ieronimaki E.; Lyroni K.; Troullinaki M.; Fujii C.; Kanczkowski W.; Ziogas A.; Peitzsch M.; Grossklaus S.; S&#xF6;nnichsen B.; Gravanis A.; Bornstein S.R.; Charalampopoulos I.; Tsatsanis C.; Chavakis T.; DHEA inhibits acute microglia-mediated inflammation through activation of the TrkA-Akt1\/2-CREB-Jmjd3 pathway. Mol Psychiatry  2018,23(6),1410-1420","journal-title":"Mol Psychiatry"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1210\/endo.140.8.6907","volume":"140","author":"Zwain I.H.","year":"1999","unstructured":"Zwain I.H.; Yen S.S.C.; Neurosteroidogenesis in astrocytes, oligodendrocytes, and neurons of cerebral cortex of rat brain. Endocrinology  1999,140(8),3843-3852","journal-title":"Endocrinology"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/glia.1117","volume":"36","author":"Gago N.","year":"2001","unstructured":"Gago N.; Akwa Y.; Sanan&#xE8;s N.; Guennoun R.; Baulieu E.E.; El-Etr M.; Schumacher M.; Progesterone and the oligodendroglial lineage: Stage-dependent biosynthesis and metabolism. Glia  2001,36(3),295-308","journal-title":"Glia"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jsbmb.2007.12.013","volume":"109","author":"Gottfried-Blackmore A.","year":"2008","unstructured":"Gottfried-Blackmore A.; Sierra A.; Jellinck P.H.; McEwen B.S.; Bulloch K.; Brain microglia express steroid-converting enzymes in the mouse. J Steroid Biochem Mol Biol  2008,109(1-2),96-107","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.cell.2011.03.050","volume":"145","author":"Saijo K.","year":"2011","unstructured":"Saijo K.; Collier J.G.; Li A.C.; Katzenellenbogen J.A.; Glass C.K.; An ADIOL-ER&#x3B2;-CtBP transrepression pathway negatively regulates microglia-mediated inflammation. Cell  2011,145(4),584-595","journal-title":"Cell"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"E313","DOI":"10.1152\/ajpendo.00418.2015","volume":"310","author":"Schaufelberger S.A.","year":"2016","unstructured":"Schaufelberger S.A.; Rosselli M.; Barchiesi F.; Gillespie D.G.; Jackson E.K.; Dubey R.K.; 2-Methoxyestradiol, an endogenous 17&#x3B2;-estradiol metabolite, inhibits microglial proliferation and activation via an estrogen receptor-independent mechanism. Am J Physiol Endocrinol Metab  2016,310(5),E313-E322","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jsbmb.2014.10.002","volume":"145","author":"Ishihara Y.","year":"2015","unstructured":"Ishihara Y.; Itoh K.; Ishida A.; Yamazaki T.; Selective estrogen-receptor modulators suppress microglial activation and neuronal cell death via an estrogen receptor-dependent pathway. J Steroid Biochem Mol Biol  2015,145,85-93","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/jnr.20583","volume":"81","author":"Liu X.","year":"2005","unstructured":"Liu X.; Fan X.L.; Zhao Y.; Luo G.R.; Li X.P.; Li R.; Le W.D.; Estrogen provides neuroprotection against activated microglia-induced dopaminergic neuronal injury through both estrogen receptor-&#x3B1; and estrogen receptor-&#x3B2; in microglia. J Neurosci Res  2005,81(5),653-665","journal-title":"J Neurosci Res"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.1210\/endo.141.10.7693","volume":"141","author":"Bruce-Keller A.J.","year":"2000","unstructured":"Bruce-Keller A.J.; Keeling J.L.; Keller J.N.; Huang F.F.; Camondola S.; Mattson M.P.; Antiinflammatory effects of estrogen on microglial activation. Endocrinology  2000,141(10),3646-3656","journal-title":"Endocrinology"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/glia.20162","volume":"50","author":"Pawlak J.","year":"2005","unstructured":"Pawlak J.; Karolczak M.; Krust A.; Chambon P.; Beyer C.; Estrogen receptor-? is associated with the plasma membrane of astrocytes and coupled to the MAP\/Src-kinase pathway. Glia  2005,50(3),270-275","journal-title":"Glia"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/glia.20644","volume":"56","author":"Sierra A.","year":"2008","unstructured":"Sierra A.; Gottfried-Blackmore A.; Milner T.A.; McEwen B.S.; Bulloch K.; Steroid hormone receptor expression and function in microglia. Glia  2008,56(6),659-674","journal-title":"Glia"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"12950","DOI":"10.1523\/JNEUROSCI.1158-10.2010","volume":"30","author":"Kuo J.","year":"2010","unstructured":"Kuo J.; Hamid N.; Bondar G.; Prossnitz E.R.; Micevych P.; Membrane estrogen receptors stimulate intracellular calcium release and progesterone synthesis in hypothalamic astrocytes. J Neurosci  2010,30(39),12950-12957","journal-title":"J Neurosci"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1210\/en.2012-2109","volume":"154","author":"Bali N.","year":"2013","unstructured":"Bali N.; Arimoto J.M.; Morgan T.E.; Finch C.E.; Progesterone antagonism of neurite outgrowth depends on microglial activation via Pgrmc1\/S2R. Endocrinology  2013,154(7),2468-2480","journal-title":"Endocrinology"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.neuroscience.2012.11.039","volume":"231","author":"Meffre D.","year":"2013","unstructured":"Meffre D.; Labombarda F.; Delespierre B.; Chastre A.; De Nicola A.F.; Stein D.G.; Schumacher M.; Guennoun R.; Distribution of membrane progesterone receptor alpha in the male mouse and rat brain and its regulation after traumatic brain injury. Neuroscience  2013,231,111-124","journal-title":"Neuroscience"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"e0165197","DOI":"10.1371\/journal.pone.0165197","volume":"11","author":"Roche S.L.","year":"2016","unstructured":"Roche S.L.; Wyse-Jackson A.C.; G&#xF3;mez-Vicente V.; Lax P.; Ruiz-Lopez A.M.; Byrne A.M.; Cuenca N.; Cotter T.G.; Progesterone attenuates microglial-driven retinal degeneration and stimulates protective fractalkine-CX3CR1 signaling. PLoS One  2016,11(11),e0165197","journal-title":"PLoS One"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/glia.21087","volume":"59","author":"Lee M.","year":"2011","unstructured":"Lee M.; Schwab C.; Mcgeer P.L.; Astrocytes are GABAergic cells that modulate microglial activity. Glia  2011,59(1),152-165","journal-title":"Glia"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.pneurobio.2003.09.001","volume":"71","author":"Lambert J.J.","year":"2003","unstructured":"Lambert J.J.; Belelli D.; Peden D.R.; Vardy A.W.; Peters J.A.; Neurosteroid modulation of GABAA receptors. Prog Neurobiol  2003,71(1),67-80","journal-title":"Prog Neurobiol"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3389\/fnins.2013.00159","volume":"7","author":"Singh M.","year":"2013","unstructured":"Singh M.; Su C.; Ng S.; Non-genomic mechanisms of progesterone action in the brain. Front Neurosci  2013,7,159","journal-title":"Front Neurosci"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.neuropharm.2016.09.007","volume":"111","author":"Pediaditakis I.","year":"2016","unstructured":"Pediaditakis I.; Efstathopoulos P.; Prousis K.C.; Zervou M.; Ar&#xE9;valo J.C.; Alexaki V.I.; Nikoletopoulou V.; Karagianni E.; Potamitis C.; Tavernarakis N.; Chavakis T.; Margioris A.N.; Venihaki M.; Calogeropoulou T.; Charalampopoulos I.; Gravanis A.; Selective and differential interactions of BNN27, a novel C17-spiroepoxy steroid derivative, with TrkA receptors, regulating neuronal survival and differentiation. Neuropharmacology  2016,111,266-282","journal-title":"Neuropharmacology"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1002\/glia.23170","volume":"65","author":"Bonetto G.","year":"2017","unstructured":"Bonetto G.; Charalampopoulos I.; Gravanis A.; Karagogeos D.; The novel synthetic microneurotrophin BNN27 protects mature oligodendrocytes against cuprizone-induced death, through the NGF receptor TrkA. Glia  2017,65(8),1376-1394","journal-title":"Glia"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.neuropharm.2017.04.043","volume":"121","author":"Botsakis K.","year":"2017","unstructured":"Botsakis K.; Mourtzi T.; Panagiotakopoulou V.; Vreka M.; Stathopoulos G.T.; Pediaditakis I.; Charalampopoulos I.; Gravanis A.; Delis F.; Antoniou K.; Zisimopoulos D.; Georgiou C.D.; Panagopoulos N.T.; Matsokis N.; Angelatou F.; BNN-20, a synthetic microneurotrophin, strongly protects dopaminergic neurons in the &#x201C;weaver&#x201D; mouse, a genetic model of dopamine-denervation, acting through the TrkB neurotrophin receptor. Neuropharmacology  2017,121,140-157","journal-title":"Neuropharmacology"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"4916","DOI":"10.1210\/en.2010-0371","volume":"151","author":"Brown C.M.","year":"2010","unstructured":"Brown C.M.; Mulcahey T.A.; Filipek N.C.; Wise P.M.; Production of proinflammatory cytokines and chemokines during neuroinflammation: Novel roles for estrogen receptors &#x3B1; and &#x3B2;. Endocrinology  2010,151(10),4916-4925","journal-title":"Endocrinology"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s11064-010-0336-7","volume":"36","author":"Smith J.A.","year":"2011","unstructured":"Smith J.A.; Das A.; Butler J.T.; Ray S.K.; Banik N.L.; Estrogen or estrogen receptor agonist inhibits lipopolysaccharide induced microglial activation and death. Neurochem Res  2011,36(9),1587-1593","journal-title":"Neurochem Res"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"9614","DOI":"10.1073\/pnas.1531957100","volume":"100","author":"Vegeto E.","year":"2003","unstructured":"Vegeto E.; Belcredito S.; Etteri S.; Ghisletti S.; Brusadelli A.; Meda C.; Krust A.; Dupont S.; Ciana P.; Chambon P.; Maggi A.; Estrogen receptor-&#x3B1; mediates the brain antiinflammatory activity of estradiol. Proc Natl Acad Sci  2003,100(16),9614-9619","journal-title":"Proc Natl Acad Sci"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1073\/pnas.1300313110","volume":"110","author":"Wu W.","year":"2013","unstructured":"Wu W.; Tan X.; Dai Y.; Krishnan V.; Warner M.; Gustafsson J.&#xC5;.; Targeting estrogen receptor &#x3B2; in microglia and T cells to treat experimental autoimmune encephalomyelitis. Proc Natl Acad Sci  2013,110(9),3543-3548","journal-title":"Proc Natl Acad Sci"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1073\/pnas.0915139107","volume":"107","author":"Bhat R.","year":"2010","unstructured":"Bhat R.; Axtell R.; Mitra A.; Miranda M.; Lock C.; Tsien R.W.; Steinman L.; Inhibitory role for GABA in autoimmune inflammation. Proc Natl Acad Sci  2010,107(6),2580-2585","journal-title":"Proc Natl Acad Sci"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/j.1365-2826.2007.01588.x","volume":"19","author":"Kipp M.","year":"2007","unstructured":"Kipp M.; Karakaya S.; Johann S.; Kampmann E.; Mey J.; Beyer C.; Oestrogen and progesterone reduce lipopolysaccharide-induced expression of tumour necrosis factor-&#x3B1; and interleukin-18 in midbrain astrocytes. J Neuroendocrinol  2007,19(10),819-822","journal-title":"J Neuroendocrinol"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"6569","DOI":"10.1021\/jm900468p","volume":"52","author":"Calogeropoulou T.","year":"2009","unstructured":"Calogeropoulou T.; Avlonitis N.; Minas V.; Alexi X.; Pantzou A.; Charalampopoulos I.; Zervou M.; Vergou V.; Katsanou E.S.; Lazaridis I.; Alexis M.N.; Gravanis A.; Novel dehydroepiandrosterone derivatives with antiapoptotic, neuroprotective activity. J Med Chem  2009,52(21),6569-6587","journal-title":"J Med Chem"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"9005","DOI":"10.18632\/oncotarget.14667","volume":"8","author":"Gravanis A.","year":"2017","unstructured":"Gravanis A.; Pediaditakis I.; Charalampopoulos I.; Synthetic microneurotrophins in therapeutics of neurodegeneration. Oncotarget  2017,8(6),9005-9006","journal-title":"Oncotarget"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S0278-5846(03)00161-1","volume":"27","author":"Akhondzadeh S.","year":"2003","unstructured":"Akhondzadeh S.; Nejatisafa A.A.; Amini H.; Mohammadi M.R.; Larijani B.; Kashani L.; Raisi F.; Kamalipour A.; Adjunctive estrogen treatment in women with chronic schizophrenia: A double-blind, randomized, and placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry  2003,27(6),1007-1012","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3371\/CSRP.GHFA.01062013","volume":"6","author":"Ghafari E.","year":"2013","unstructured":"Ghafari E.; Fararouie M.; Shirazi H.G.; Farhangfar A.; Ghaderi F.; Mohammadi A.; Combination of estrogen and antipsychotics in the treatment of women with chronic schizophrenia: A double-blind, randomized, placebo-controlled clinical trial. Clin Schizophr Relat Psychoses  2013,6(4),172-176","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/2008-2231-22-55","volume":"22","author":"Kianimehr G.","year":"2014","unstructured":"Kianimehr G.; Fatehi F.; Hashempoor S.; Khodaei-Ardakani M.R.; Rezaei F.; Nazari A.; Kashani L.; Akhondzadeh S.; Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: A randomized double-blind and placebo controlled trial. Daru  2014,22(1),55","journal-title":"Daru"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/archpsyc.65.8.955","volume":"65","author":"Kulkarni J.","year":"2008","unstructured":"Kulkarni J.; de Castella A.; Fitzgerald P.B.; Gurvich C.T.; Bailey M.; Bartholomeusz C.; Burger H.; Estrogen in severe mental illness: A potential new treatment approach. Arch Gen Psychiatry  2008,65(8),955-960","journal-title":"Arch Gen Psychiatry"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.schres.2010.10.009","volume":"125","author":"Kulkarni J.","year":"2011","unstructured":"Kulkarni J.; de Castella A.; Headey B.; Marston N.; Sinclair K.; Lee S.; Gurvich C.; Fitzgerald P.B.; Burger H.; Estrogens and men with schizophrenia: Is there a case for adjunctive therapy? Schizophr Res  2011,125(2-3),278-283","journal-title":"Schizophr Res"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0920-9964(00)00088-8","volume":"48","author":"Kulkarni J.","year":"2001","unstructured":"Kulkarni J.; Riedel A.; de Castella A.R.; Fitzgerald P.B.; Rolfe T.J.; Taffe J.; Burger H.; Estrogen: A potential treatment for schizophrenia. Schizophr Res  2001,48(1),137-144","journal-title":"Schizophr Res"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jamapsychiatry.2016.1383","volume":"73","author":"Kulkarni J.","year":"2016","unstructured":"Kulkarni J.; Gavrilidis E.; Gwini S.M.; Worsley R.; Grigg J.; Warren A.; Gurvich C.; Gilbert H.; Berk M.; Davis S.R.; Effect of adjunctive raloxifene therapy on severity of refractory schizophrenia in women. JAMA Psychiatry  2016,73(9),947-954","journal-title":"JAMA Psychiatry"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0920-9964(03)00082-3","volume":"66","author":"Louz&#xE3; M.R.","year":"2004","unstructured":"Louz&#xE3; M.R.; Marques A.P.; Elkis H.; Bassitt D.; Diegoli M.; Gattaz W.F.; Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: A double-blind study. Schizophr Res  2004,66(2-3),97-100","journal-title":"Schizophr Res"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/schbul\/sbv149","volume":"42","author":"Usall J.","year":"2016","unstructured":"Usall J.; Huerta-Ramos E.; Labad J.; Cobo J.; N&#xFA;&#xF1;ez C.; Creus M.; Par&#xE9;s G.G.; Cuadras D.; Franco J.; Miquel E.; Reyes J.C.; Roca M.; Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: A 24-week double-blind, randomized, parallel, placebo-controlled trial. Schizophr Bull  2016,42(2),309-317","journal-title":"Schizophr Bull"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"e758","DOI":"10.4088\/JCP.15m10498","volume":"78","author":"Weiser M.","year":"2017","unstructured":"Weiser M.; Levi L.; Burshtein S.; Hagin M.; Matei V.P.; Podea D.; Miclu&#x21B;ia, I.; Tiugan, A.; P\u0103cal\u0103 B.; Grecu, I.G.; Noy, A.; Zamora, D.; Davis, J.M. Raloxifene plus antipsychotics versus placebo plus antipsychotics in severely ill decompensated postmenopausal women with schizophrenia or schizoaffective disorder. J Clin Psychiatry  2017,78(7),e758-e765","journal-title":"J Clin Psychiatry"},{"key":"ref=156","first-page":"337","volume":"53","author":"Khodaie-Ardakani M-R.","year":"2015","unstructured":"Khodaie-Ardakani M-R.; Khosravi M.; Zarinfard R.; Nejati S.; Mohsenian A.; Tabrizi M.; Akhondzadeh S.; A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia. Acta Med Iran  2015,53(6),337-345","journal-title":"Acta Med Iran"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.schres.2021.01.024","volume":"230","author":"Nasib L.G.","year":"2021","unstructured":"Nasib L.G.; Gangadin S.S.; Rossum I.W.; Boudewijns Z.S.R.M.; de Witte L.D.; Wilting I.; Luykx J.; Somers M.; Veen N.; van Baal C.; Kahn R.S.; Sommer I.E.; The effect of prednisolone on symptom severity in schizophrenia: A placebo-controlled, randomized controlled trial. Schizophr Res  2021,230,79-86","journal-title":"Schizophr Res"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0272-6386(99)70414-2","volume":"33","author":"Veenstra D.L.","year":"1999","unstructured":"Veenstra D.L.; Best J.H.; Hornberger J.; Sullivan S.D.; Hricik D.E.; Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis  1999,33(5),829-839","journal-title":"Am J Kidney Dis"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"392","DOI":"10.14744\/AnatolJCardiol.2016.7425","volume":"17","year":"2017","unstructured":"&#xC7;ald\u0131r, M.V.; &#xC7;elik, G.K.; &#xC7;ift&#xE7;i, &#xD6;.; M&#xFC;derriso&#x11F;lu, \u0130.H. The effect of high-dose steroid treatment used for the treatment of acute demyelinating diseases on endothelial and cardiac functions. Anatol J Cardiol  2017,17(5),392-397","journal-title":"Anatol J Cardiol"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","volume":"10","author":"De Hert M.","year":"2011","unstructured":"De Hert M.; Correll C.U.; Bobes J.; Cetkovich-Bakmas M.; Cohen D.; Asai I.; Detraux J.; Gautam S.; M&#xF6;ller H.J.; Ndetei D.M.; Newcomer J.W.; Uwakwe R.; Leucht S.; Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry  2011,10(1),52-77","journal-title":"World Psychiatry"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1192\/j.eurpsy.2020.115","volume":"64","author":"Galderisi S.","year":"2021","unstructured":"Galderisi S.; De Hert M.; Del Prato S.; Fagiolini A.; Gorwood P.; Leucht S.; Maggioni A.P.; Mucci A.; Arango C.; Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study. Eur Psychiatry  2021,64(1),e7","journal-title":"Eur Psychiatry"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"414","DOI":"10.4088\/JCP.10r06823","volume":"73","author":"Sommer I.E.","year":"2012","unstructured":"Sommer I.E.; de Witte L.; Begemann M.; Kahn R.S.; Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry  2012,73(4),414-419","journal-title":"J Clin Psychiatry"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1006\/mcne.1998.0731","volume":"13","author":"Hirst W.D.","year":"1999","unstructured":"Hirst W.D.; Young K.A.; Newton R.; Allport V.C.; Marriott D.R.; Wilkin G.P.; Expression of COX-2 by normal and reactive astrocytes in the adult rat central nervous system. Mol Cell Neurosci  1999,13(1),57-68","journal-title":"Mol Cell Neurosci"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/jnen\/63.9.901","volume":"63","author":"Minghetti L.","year":"2004","unstructured":"Minghetti L.; Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol  2004,63(9),901-910","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1176\/appi.ajp.159.6.1029","volume":"159","author":"M&#xFC;ller N.","year":"2002","unstructured":"M&#xFC;ller N.; Riedel M.; Scheppach C.; Brandst&#xE4;tter B.; Sokullu S.; Krampe K.; Ulmschneider M.; Engel R.R.; M&#xF6;ller H.J.; Schwarz M.J.; Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry  2002,159(6),1029-1034","journal-title":"Am J Psychiatry"},{"key":"ref=166","author":"M&#xFC;ller N","year":"2004","unstructured":"M&#xFC;ller N; Riedel M; Schwarz MJ; Engel RR;   2004"},{"key":"ref=167","first-page":"31","volume":"11","author":"M&#xFC;ller N.","year":"2010","unstructured":"M&#xFC;ller N.; COX-2 inhibitors as antidepressants and antipsychotics: Clinical evidence. Curr Opin Investig Drugs  2010,11(1),31-42","journal-title":"Curr Opin Investig Drugs"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"520","DOI":"10.4088\/JCP.09m05117yel","volume":"71","author":"Laan W.","year":"2010","unstructured":"Laan W.; Grobbee D.E.; Selten J.P.; Heijnen C.J.; Kahn R.S.; Burger H.; Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: Results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry  2010,71(5),520-527","journal-title":"J Clin Psychiatry"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/schbul\/sbt070","volume":"39","author":"Nitta M.","year":"2013","unstructured":"Nitta M.; Kishimoto T.; M&#xFC;ller N.; Weiser M.; Davidson M.; Kane J.M.; Correll C.U.; Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials. Schizophr Bull  2013,39(6),1230-1241","journal-title":"Schizophr Bull"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/BF03191015","volume":"33","year":"2008","unstructured":"Vasovi\u0107 V.; Bani\u0107 B.; Jakovljevi\u0107 V.; Tomic, Z.; Milic-Djordjevic, V. Effect of aminophylline on aspirin penetration into the central nervous system in rats. Eur J Drug Metab Pharmacokinet  2008,33(1),23-30","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/ana.10242","volume":"52","author":"Arvin K.L.","year":"2002","unstructured":"Arvin K.L.; Han B.H.; Du Y.; Lin S.Z.; Paul S.M.; Holtzman D.M.; Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol  2002,52(1),54-61","journal-title":"Ann Neurol"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/77528","volume":"6","author":"Chen M.","year":"2000","unstructured":"Chen M.; Ona V.O.; Li M.; Ferrante R.J.; Fink K.B.; Zhu S.; Bian J.; Guo L.; Farrell L.A.; Hersch S.M.; Hobbs W.; Vonsattel J.P.; Cha J.H.J.; Friedlander R.M.; Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med  2000,6(7),797-801","journal-title":"Nat Med"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1523\/JNEUROSCI.22-05-01763.2002","volume":"22","author":"Wu D.C.","year":"2002","unstructured":"Wu D.C.; Jackson-Lewis V.; Vila M.; Tieu K.; Teismann P.; Vadseth C.; Choi D.K.; Ischiropoulos H.; Przedborski S.; Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci  2002,22(5),1763-1771","journal-title":"J Neurosci"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.brainres.2009.07.031","volume":"1291","author":"Homsi S.","year":"2009","unstructured":"Homsi S.; Federico F.; Croci N.; Palmier B.; Plotkine M.; Marchand-Leroux C.; Jafarian-Tehrani M.; Minocycline effects on cerebral edema: Relations with inflammatory and oxidative stress markers following traumatic brain injury in mice. Brain Res  2009,1291,122-132","journal-title":"Brain Res"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"13496","DOI":"10.1073\/pnas.96.23.13496","volume":"96","author":"Yrj&#xE4;nheikki J.","year":"1999","unstructured":"Yrj&#xE4;nheikki J.; Tikka T.; Kein&#xE4;nen R.; Goldsteins G.; Chan P.H.; Koistinaho J.; A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci  1999,96(23),13496-13500","journal-title":"Proc Natl Acad Sci"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"15769","DOI":"10.1073\/pnas.95.26.15769","volume":"95","author":"Yrj&#xE4;nheikki J.","year":"1998","unstructured":"Yrj&#xE4;nheikki J.; Kein&#xE4;nen R.; Pellikka M.; H&#xF6;kfelt T.; Koistinaho J.; Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci  1998,95(26),15769-15774","journal-title":"Proc Natl Acad Sci"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00213-011-2509-8","volume":"220","author":"Watabe M.","year":"2012","unstructured":"Watabe M.; Kato T.A.; Monji A.; Horikawa H.; Kanba S.; Does minocycline, an antibiotic with inhibitory effects on microglial activation, sharpen a sense of trust in social interaction? Psychopharmacology  2012,220(3),551-557","journal-title":"Psychopharmacology"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0306-4522(03)00558-X","volume":"121","author":"Dommergues M.A.","year":"2003","unstructured":"Dommergues M.A.; Plaisant F.; Verney C.; Gressens P.; Early microglial activation following neonatal excitotoxic brain damage in mice: A potential target for neuroprotection. Neuroscience  2003,121(3),619-628","journal-title":"Neuroscience"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"e525","DOI":"10.1038\/cddis.2013.54","volume":"4","author":"Kobayashi K.","year":"2013","unstructured":"Kobayashi K.; Imagama S.; Ohgomori T.; Hirano K.; Uchimura K.; Sakamoto K.; Hirakawa A.; Takeuchi H.; Suzumura A.; Ishiguro N.; Kadomatsu K.; Minocycline selectively inhibits M1 polarization of microglia. Cell Death Dis  2013,4(3),e525-e525","journal-title":"Cell Death Dis"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1523\/JNEUROSCI.21-08-02580.2001","volume":"21","author":"Tikka T.","year":"2001","unstructured":"Tikka T.; Fiebich B.L.; Goldsteins G.; Kein&#xE4;nen R.; Koistinaho J.; Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci  2001,21(8),2580-2588","journal-title":"J Neurosci"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00213-007-0955-0","volume":"196","author":"Mizoguchi H.","year":"2008","unstructured":"Mizoguchi H.; Takuma K.; Fukakusa A.; Ito Y.; Nakatani A.; Ibi D.; Kim H.C.; Yamada K.; Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice. Psychopharmacology  2008,196(2),233-241","journal-title":"Psychopharmacology"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.biopsych.2005.06.006","volume":"59","author":"Kamei H.","year":"2006","unstructured":"Kamei H.; Nagai T.; Nakano H.; Togan Y.; Takayanagi M.; Takahashi K.; Kobayashi K.; Yoshida S.; Maeda K.; Takuma K.; Nabeshima T.; Yamada K.; Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1\/2 activation in the prefrontal cortex of mice. Biol Psychiatry  2006,59(1),75-84","journal-title":"Biol Psychiatry"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.brainres.2007.03.080","volume":"1154","author":"Levkovitz Y.","year":"2007","unstructured":"Levkovitz Y.; Levi U.; Braw Y.; Cohen H.; Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res  2007,1154,154-162","journal-title":"Brain Res"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.pnpbp.2007.08.031","volume":"32","author":"Fujita Y.","year":"2008","unstructured":"Fujita Y.; Ishima T.; Kunitachi S.; Hagiwara H.; Zhang L.; Iyo M.; Hashimoto K.; Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog Neuropsychopharmacol Biol Psychiatry  2008,32(2),336-339","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.expneurol.2004.01.011","volume":"189","author":"Tsuji M.","year":"2004","unstructured":"Tsuji M.; Wilson M.A.; Lange M.S.; Johnston M.V.; Minocycline worsens hypoxic-ischemic brain injury in a neonatal mouse model. Exp Neurol  2004,189(1),58-65","journal-title":"Exp Neurol"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/glia.22612","volume":"62","author":"Arnoux I.","year":"2014","unstructured":"Arnoux I.; Hoshiko M.; Sanz Diez A.; Audinat E.; Paradoxical effects of minocycline in the developing mouse somatosensory cortex. Glia  2014,62(3),399-410","journal-title":"Glia"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nn.3358","volume":"16","author":"Ueno M.","year":"2013","unstructured":"Ueno M.; Fujita Y.; Tanaka T.; Nakamura Y.; Kikuta J.; Ishii M.; Yamashita T.; Layer V cortical neurons require microglial support for survival during postnatal development. Nat Neurosci  2013,16(5),543-551","journal-title":"Nat Neurosci"},{"key":"ref=188","first-page":"493","volume":"43","author":"Inta D.","year":"2017","unstructured":"Inta D.; Lang U.E.; Borgwardt S.; Meyer-Lindenberg A.; Gass P.; Microglia activation and schizophrenia: Lessons from the effects of minocycline on postnatal neurogenesis, neuronal survival and synaptic pruning. Schizophr Bull  2017,43(3),493-496","journal-title":"Schizophr Bull"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"138","DOI":"10.4088\/JCP.08m04666yel","volume":"71","author":"Levkovitz Y.","year":"2010","unstructured":"Levkovitz Y.; Mendlovich S.; Riwkes S.; Braw Y.; Levkovitch-Verbin H.; Gal G.; Fennig S.; Treves I.; Kron S.; A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry  2010,71(2),138-149","journal-title":"J Clin Psychiatry"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1177\/0269881112444941","volume":"26","author":"Chaudhry I.B.","year":"2012","unstructured":"Chaudhry I.B.; Hallak J.; Husain N.; Minhas F.; Stirling J.; Richardson P.; Dursun S.; Dunn G.; Deakin B.; Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol  2012,26(9),1185-1193","journal-title":"J Psychopharmacol"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"E06","DOI":"10.1176\/appi.neuropsych.11120376","volume":"25","author":"Jhamnani K.","year":"2013","unstructured":"Jhamnani K.; Shivakumar V.; Kalmady S.; Rao N.P.; Venkatasubramanian G.; Successful use of add-on minocycline for treatment of persistent negative symptoms in schizophrenia. J Neuropsychiatry Clin Neurosci  2013,25(1),E06-E07","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.schres.2011.08.005","volume":"133","author":"Kelly D.L.","year":"2011","unstructured":"Kelly D.L.; Vyas G.; Richardson C.M.; Koola M.; McMahon R.P.; Buchanan R.W.; Wehring H.J.; Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. Schizophr Res  2011,133(1-3),257-258","journal-title":"Schizophr Res"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/WNF.0b013e3181593d45","volume":"31","author":"Miyaoka T.","year":"2008","unstructured":"Miyaoka T.; Yasukawa R.; Yasuda H.; Hayashida M.; Inagaki T.; Horiguchi J.; Minocycline as adjunctive therapy for schizophrenia: An open-label study. Clin Neuropharmacol  2008,31(5),287-292","journal-title":"Clin Neuropharmacol"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.pnpbp.2007.01.018","volume":"31","author":"Ahuja N.","year":"2007","unstructured":"Ahuja N.; Carroll B.T.; Possible anti-catatonic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry  2007,31(4),968-969","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.pnpbp.2010.01.020","volume":"34","author":"Chaves C.","year":"2010","unstructured":"Chaves C.; de Marque C.R.; Wichert-Ana L.; Maia-de-Oliveira J.P.; Itikawa E.N.; Crippa J.A.S.; Zuardi A.W.; Todd K.G.; Baker G.B.; Dursun S.M.; Hallak J.E.C.; Functional neuroimaging of minocycline\u2019s effect in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry  2010,34(3),550-552","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.2147\/NDT.S179658","volume":"14","author":"Chen X.","year":"2018","unstructured":"Chen X.; Xiong Z.; Li Z.; Yang Y.; Zheng Z.; Li Y.; Xie Y.; Li Z.; Minocycline as adjunct therapy for a male patient with deficit schizophrenia. Neuropsychiatr Dis Treat  2018,14,2697-2701","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1017\/S1092852916000638","volume":"22","author":"Solmi M.","year":"2017","unstructured":"Solmi M.; Veronese N.; Thapa N.; Facchini S.; Stubbs B.; Fornaro M.; Carvalho A.F.; Correll C.U.; Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. CNS Spectr  2017,22(5),415-426","journal-title":"CNS Spectr"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S2215-0366(18)30345-6","volume":"5","author":"Deakin B.","year":"2018","unstructured":"Deakin B.; Suckling J.; Barnes T.R.E.; Byrne K.; Chaudhry I.B.; Dazzan P.; Drake R.J.; Giordano A.; Husain N.; Jones P.B.; Joyce E.; Knox E.; Krynicki C.; Lawrie S.M.; Lewis S.; Lisiecka-Ford D.M.; Nikkheslat N.; Pariante C.M.; Smallman R.; Watson A.; Williams S.C.R.; Upthegrove R.; Dunn G.; The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): A randomised, double-blind, placebo-controlled trial. Lancet Psychiatry  2018,5(11),885-894","journal-title":"Lancet Psychiatry"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1136\/ebmental-2018-300070","volume":"22","author":"Solmi M.","year":"2019","unstructured":"Solmi M.; Correll C.U.; Adjunctive minocycline in schizophrenia: What one well-conducted study can tell us (and what it can\u2019t). Evid Based Ment Health  2019,22(1),e3-e3","journal-title":"Evid Based Ment Health"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/S2215-0366(18)30389-4","volume":"5","author":"Kishimoto T.","year":"2018","unstructured":"Kishimoto T.; Horigome T.; Takamiya A.; Minocycline as a treatment for schizophrenia: is the discussion truly finished? Lancet Psychiatry  2018,5(11),856-857","journal-title":"Lancet Psychiatry"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.bbi.2020.08.028","volume":"90","author":"Jeppesen R.","year":"2020","unstructured":"Jeppesen R.; Christensen R.H.B.; Pedersen E.M.J.; Nordentoft M.; Hjorth&#xF8;j C.; K&#xF6;hler-Forsberg O.; Benros M.E.; Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders: A comprehensive systematic review and meta-analysis. Brain Behav Immun  2020,90,364-380","journal-title":"Brain Behav Immun"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3389\/fpsyt.2019.00375","volume":"10","author":"M&#xFC;ller N.","year":"2019","unstructured":"M&#xFC;ller N.; COX-2 inhibitors, aspirin, and other potential anti-inflammatory treatments for psychiatric disorders. Front Psychiatry  2019,10,375","journal-title":"Front Psychiatry"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pnpbp.2018.04.004","volume":"85","author":"Zhang L.","year":"2018","unstructured":"Zhang L.; Zheng H.; Wu R.; Zhu F.; Kosten T.R.; Zhang X.Y.; Zhao J.; Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels. Prog Neuropsychopharmacol Biol Psychiatry  2018,85,69-76","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X22666231128101725","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/223930\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X22666231128101725","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T17:05:49Z","timestamp":1713373549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/223930\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":203,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x22666231128101725","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-11-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}